Lentiviral vectors: Optimization of packaging, transduction and gene expression

Journal of Gene Medicine

Volumn 6, Issue SUPPL. 1, 2004, Pages

  Delenda, Christophe ^a  

^a GÉNÉTHON   (France)

Author keywords

Gene expression; Gene therapy; Lentiviral vectors; Packaging; Transduction

Indexed keywords

BETA INTERFERON; CATECHOLAMINE DERIVATIVE; DIPHTHERIA TOXIN; DNA DIRECTED RNA POLYMERASE III; ENZYME; GAG PROTEIN; GLYCOPROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN KAPPA CHAIN; LENTIVIRUS VECTOR; PLASMID DNA; POL PROTEIN; RNA; SMALL INTERFERING RNA;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; DNA MODIFICATION; DNA PACKAGING; EXON; GENE EXPRESSION; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; GENE TRANSFER; GENETIC TRANSDUCTION; GENOME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRINAE; NONHUMAN; OPEN READING FRAME; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; REGULATOR GENE; REVIEW; RNA SPLICING; TRANSCRIPTION REGULATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CAPSID; ANIMAL; GENE DELETION; GENE VECTOR; GENETICS; PHYSIOLOGY; VIRUS ASSEMBLY;

MAMMALIA;

ANIMALS; GENE DELETION; GENE EXPRESSION; GENETIC VECTORS; HUMANS; LENTIVIRUS; RNA POLYMERASE III; TRANSDUCTION, GENETIC; VIRUS ASSEMBLY;

EID: 4644318481     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.501     Document Type: Review

References (180)

1. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector [see comments]. Science 1996; 272: 263-267.
2. Poeschla E, Gilbert J, Li X, Huang S, Ho A, Wong-Staal F. Identification of a human immunodeficiency virus type 2 (HIV-2) encapsidation determinant and transduction of nondividing human cells by HIV-2-based lentivirus vectors. J Virol 1998; 72: 6527-6536.
3. Mangeot PE, Negre D, Dubois B, et al. Development of minimal lentivirus vectors derived from simian immunodeficiency virus (SIVmac251) and their use for gene transfer into human dendritic cells. J Virol 2000; 74: 8307-8315.
4. Poeschla EM, Wong-Staal F, Looney DJ. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998; 4: 354-357.
5. Berkowitz R, Ilves H, Lin WY, et al. Construction and molecular analysis of gene transfer systems derived from bovine immunodeficiency virus. J Virol 2001; 75: 3371-3382.
6. Mselli-Lakhal L, Favier C, Da Silva Teixeira MF, et al. Defective RNA packaging is responsible for low transduction efficiency of CAEV-based vectors. Arch Virol 1998; 143: 681-695.
7. Olsen JC. Gene transfer vectors derived from equine infectious anemia virus. Gene Ther 1998; 5: 1481-1487.
8. Mitrophanous K, Yoon S, Rohll J, et al. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther 1999; 6: 1808-1818.
9. Metharom P, Takyar S, Xia HH, et al. Novel bovine lentiviral vectors based on Jembrana disease virus. J Gene Med 2000; 2: 176-185.
10. Fletcher TM III, Brichacek B, Sharova N, et al. Nuclear import and cell cycle arrest functions of the HIV-1 Vpr protein are encoded by two separate genes in HIV-2/SIV(SM). EMBO J 1996; 15 6155-6165.
11. Bukrinsky M, Adzhubei A. Viral protein R of HIV-1. Rev Med Virol 1999; 9: 39-49.
12. Luo W, Peterlin BM. Activation of the T-cell receptor signaling pathway by Nef from an aggressive strain of simian immunodeficiency virus. J Virol 1997; 71: 9531-9537.
13. Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, Jolicoeur P. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 1998; 95: 163-175.
14. Piguet V, Schwartz O, Le Gall S, Trono D. The downregulation of CD4 and MHC-I by primate lentiviruses: a paradigm for the modulation of cell surface receptors. Immunol Rev 1999; 168: 51-63.
15. Pandori MW, Fitch NJ, Craig HM, Richman DD, Spina CA, Guatelli JC. Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J Virol 1996; 70: 4283-4290.
16. Camaur D, Trono D. Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J Virol 1996; 70: 6106-6111.
17. Sato A, Yoshimoto J, Isaka Y, et al. Evidence for direct association of Vpr and matrix protein p17 within the HIV-1 virion. Virology 1996; 220: 208-212.
18. Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
19. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol 1998; 72: 8463-8471.
20. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17: 314-317.
21. Chinnasamy D, Chinnasamy N, Enriquez MJ, Otsu M, Morgan RA, Candotti F. Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins. Blood 2000; 96: 1309-1316.
22. Costello E, Munoz M, Buetti E, Meylan PR, Diggelmann H, Thali M. Gene transfer into stimulated and unstimulated T lymphocytes by HIV-1-derived lentiviral vectors. Gene Ther 2000; 7: 596-604.
23. Rossi GR, Mautino MR, Morgan RA. High-efficiency lentiviral vector-mediated gene transfer into murine macrophages and activated splenic B lymphocytes. Hum Gene Ther 2003; 14: 385-391.
24. Negre D, Mangeot PE, Duisit G, et al. Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells [in process citation]. Gene Ther 2000; 7: 1613-1623.
25. Mangeot PE, Duperrier K, Negre D, et al. High levels of transduction of human dendritic cells with optimized SIV vectors. Mol Ther 2002; 5: 283-290.
26. Johnston JC, Gasmi M, Lim LE, et al. Minimum requirements for efficient transduction of dividing and nondividing cells by feline immunodeficiency virus vectors. J Virol 1999; 73: 4991-5000.
27. Molina RP, Matukonis M, Paszkiet B, Zhang J, Kaleko M, Luo T. Mapping of the bovine immunodeficiency virus packaging signal and RRE and incorporation into a minimal gene transfer vector. Virology 2002; 304: 10-23.
28. Kim VN, Mitrophanous K, Kingsman SM, Kingsman AJ. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 1998; 72: 811-816.
29. Miyoshi H, Blomer U, Takahashi M, Gage FH, Verma IM. Development of a self-inactivating lentivirus vector. J Virol 1998; 72: 8150-8157.
30. Gasmi M, Glynn J, Jin MJ, Jolly DJ, Yee JK, Chen ST. Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors. J Virol 1999; 73 1828-1834.
31. Srinivasakumar N, Schuening FG. A lentivirus packaging system based on alternative RNA transport mechanisms to express helper and gene transfer vector RNAs and its use to study the requirement of accessory proteins for particle formation and gene delivery. J Virol 1999; 73: 9589-9598.
32. Curran MA, Kaiser SM, Achacoso PL, Nolan GP. Efficient transduction of nondividing cells by optimized feline immunodeficiency virus vectors. Mol Ther 2000; 1: 31-38.
33. Mautino MR, Keiser N, Morgan RA. Improved titers of HIV-based lentiviral vectors using the SRV-1 constitutive transport element. Gene Ther 2000; 7: 1421-1424.
34. Nappi F, Schneider R, Zolotukhin A, et al. Identification of a novel posttranscriptional regulatory element by using a rev- and RRE-mutated human immunodeficiency virus type 1 DNA proviral clone as a molecular trap. J Virol 2001; 75: 4558-4569.
35. Pandya S, Boris-Lawrie K, Leung NJ, Akkina R, Planelles V. Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system. Hum Gene Ther 2001; 12: 847-857.
36. Roberts TM, Boris-Lawrie K. The 5′ RNA terminus of spleen necrosis virus stimulates translation of nonviral mRNA. J Virol 2000; 74: 8111-8118.
37. Reddy TR, Xu W, Mau JK, et al. Inhibition of HIV replication by dominant negative mutants of Sam68, a functional homolog of HIV-1 Rev.Nat Med 1999; 5: 635-642.
38. Kotsopoulou E, Kim VN, Kingsman AJ, Kingsman SM, Mitrophanous KA. A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol 2000; 74: 4839-4852.
39. Wagner R, Graf M, Bieler K, et al. Rev-independent expression of synthetic gag-pol genes of human immunodeficiency virus type 1 and simian immunodeficiency virus: implications for the safety of lentiviral vectors [in process citation]. Hum Gene Ther 2000; 11 2403-2413.
40. Kuate S, Wagner R, Uberla K. Development and characterization of a minimal inducible packaging cell line for simian immunodeficiency virus-based lentiviral vectors. J Gene Med 2002; 4: 347-355.
41. Wu X, Wakefield JK, Liu H, et al. Development of a novel translentiviral vector that affords predictable safety. Mol Ther 2000; 2: 47-55.
42. Cherepanov P, Pluymers W, Claeys A, Proost P, De Clercq E, Debyser Z. High-level expression of active HIV-1 integrase from a synthetic gene in human cells. FASEB J 2000; 14: 1389-1399.
43. Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD. Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nat Med 2003; 9: 1138-1143.
44. Kootstra NA, Munk C, Tonnu N, Landau NR, Verma IM. Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proc Natl Acad Sci U S A 2003; 100: 1298-1303.
45. Corbeau P, Kraus G, Wong-Staal F. Transduction of human macrophages using a stable HIV-1/HIV-2-derived gene delivery system. Gene Ther 1998; 5: 99-104.
46. Stitz J, Muhlebach MD, Blomer U, et al. A novel lentivirus vector derived from apathogenic simian immunodeficiency virus. Virology 2001; 291: 191-197.
47. Goujon C, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix JL, Cimarelli A. Heterologous human immunodeficiency virus type 1 lentiviral vectors packaging a simian immunodeficiency virus-derived genome display a specific postentry transduction defect in dendritic cells. J Virol 2003; 77: 9295-9304.
48. Negre D, Mangeot PE, Duisit G, et al. Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther 2000; 7: 1613-1623.
49. D'Costa J, Harvey-White J, Qasba P, et al. HIV-2 derived lentiviral vectors: gene transfer in Parkinson's and Fabry disease models in vitro. J Med Virol 2003; 71: 173-182.
50. Browning MT, Schmidt RD, Lew KA, Rizvi TA. Primate and feline lentivirus vector RNA packaging and propagation by heterologous lentivirus virions. J Virol 2001; 75: 5129-5140.
51. Zennou V, Petit C, Guetard D, Nerhbass U, Montagnier L, Charneau P. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000; 101: 173-185.
52. Follenzi A, Ailles LE, Bakovic S, Geuna M, Naldini L. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25: 217-222.
53. Ilyinskii PO, Desrosiers RC. Identification of a sequence element immediately upstream of the polypurine tract that is essential for replication of simian immunodeficiency virus. EMBO J 1998; 17: 3766-3774.
54. Stetor SR, Rausch JW, Guo MJ, et al. Characterization of (+) strand initiation and termination sequences located at the center of the equine infectious anemia virus genome. Biochemistry 1999; 38: 3656-3667.
55. Whitwam T, Peretz M, Poeschla E. Identification of a central DNA flap in feline immunodeficiency virus. J Virol 2001; 75: 9407-9414.
56. Zufferey R, Donello JE, Trono D, Hope TJ. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73: 2886-2892.
57. O'Rourke JP, Hiraragi H, Urban K, Patel M, Olsen JC, Bunnell BA. Analysis of gene transfer and expression in skeletal muscle using enhanced EIAV lentivirus vectors. Mol Ther 2003; 7: 632-639.
58. Brun S, Faucon-Biguet N, Mallet J. Optimization of transgene expression at the posttranscriptional level in neural cells: implications for gene therapy. Mol Ther 2003; 7: 782-789.
59. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
60. Iwakuma T, Cui Y, Chang LJ. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 1999; 261: 120-132.
61. Schnell T, Foley P, Wirth M, Munch J, Uberla K. Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther 2000; 11: 439-447.
62. Zaiss AK, Son S, Chang LJ. RNA 3′ readthrough of oncoretrovirus and lentivirus: implications for vector safety and efficacy. J Virol 2002; 76: 7209-7219.
63. Swain A, Coffin JM. Mechanism of transduction by retroviruses. Science 1992; 255: 841-845.
64. Zhang QY, Clausen PA, Yatsula BA, Calothy G, Blair DG. Mutation of polyadenylation signals generates murine retroviruses that produce fused virus-cell RNA transcripts at high frequency. Virology 1998; 241: 80-93.
65. Gao Z, Golob J, Tanavde VM, Civin CI, Hawley RG, Cheng L. High levels of transgene expression following transduction of long-term NOD/SCID-repopulating human cells with a modified lentiviral vector. Stem Cells 2001; 19: 247-259.
66. Choi JK, Hoang N, Vilardi AM, Conrad P, Emerson SG, Gewirtz AM. Hybrid HIV/MSCV LTR enhances transgene expression of lentiviral vectors in human CD34(+) hematopoietic cells. Stem Cells 2001; 19: 236-246.
67. Lai Z, Han I, Park M, Brady RO. Design of an HIV-1 lentiviral-based gene-trap vector to detect developmentally regulated genes in mammalian cells. Proc Natl Acad Sci U S A 2002; 99: 3651-3656.
68. Nakajima T, Nakamaru K, Ido E, Terao K, Hayami M, Hasegawa M. Development of novel simian immunodeficiency virus vectors carrying a dual gene expression system. Hum Gene Ther 2000; 11: 1863-1874.
69. Berkhout B, van Wamel J, Klaver B. Requirements for DNA strand transfer during reverse transcription in mutant HIV-1 virions. J Mol Biol 1995; 252: 59-69.
70. Browning MT, Mustafa F, Schmidt RD, Lew KA, Rizvi TA. Delineation of sequences important for efficient packaging of feline immunodeficiency virus RNA. J Gen Virol 2003; 84: 621-627.
71. Browning MT, Mustafa F, Schmidt RD, Lew KA, Rizvi TA. Sequences within the gag gene of feline immunodeficiency virus (FIV) are important for efficient RNA encapsidation. Virus Res 2003; 93 199-209.
72. Berglund JA, Charpentier B, Rosbash M. A high affinity binding site for the HIV-1 nucleocapsid protein. Nucleic Acids Res 1997; 25: 1042-1049.
73. Clever JL, Taplitz RA, Lochrie MA, Polisky B, Parslow TG. A heterologous, high-affinity RNA ligand for human immunodeficiency virus Gag protein has RNA packaging activity. J Virol 2000; 74: 541-546.
74. Delviks KA, Hu WS, Pathak VK. Psi-vectors: murine leukemia virus-based self-inactivating and self-activating retroviral vectors. J Virol 1997; 71: 6218-6224.
75. Stutz F, Rosbash M. A functional interaction between Rev and yeast pre-mRNA is related to splicing complex formation. EMBO J 1994; 13: 4096-4104.
76. Gontarek RR, Derse D. Interactions among SR proteins, an exonic splicing enhancer, and a lentivirus Rev protein regulate alternative splicing. Mol Cell Biol 1996; 16: 2325-2331.
77. Belshan M, Park GS, Bilodeau P, Stoltzfus CM, Carpenter S. Binding of equine infectious anemia virus rev to an exon splicing enhancer mediates alternative splicing and nuclear export of viral mRNAs. Mol Cell Biol 2000; 20: 3550-3557.
78. Blencowe BJ. Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci 2000; 25: 106-110.
79. Staffa A, Cochrane A. Identification of positive and negative splicing regulatory elements within the terminal tat-rev exon of human immunodeficiency virus type 1. Mol Cell Biol 1995; 15: 4597-4605.
80. Mautino MR, Ramsey WJ, Reiser J, Morgan RA. Modified human immunodeficiency virus-based lentiviral vectors display decreased sensitivity to trans-dominant Rev. Hum Gene Ther 2000; 11: 895-908.
81. Cui Y, Iwakuma T, Chang LJ. Contributions of viral splice sites and cis-regulatory elements to lentivirus vector function. J Virol 1999; 73: 6171-6176.
82. Yoder JA, Walsh CP, Bestor TH. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet 1997; 13: 335-340.
83. Kempler G, Freitag B, Berwin B, Nanassy O, Barklis E. Characterization of the Moloney murine leukemia virus stem cell-specific repressor binding site. Virology 1993; 193: 690-699.
84. Pannell D, Osborne CS, Yao S, et al. Retrovirus vector silencing is de novo methylase independent and marked by a repressive histone code. EMBO J 2000; 19: 5884-5894.
85. Pannell D, Ellis J. Silencing of gene expression: implications for design of retrovirus vectors. Rev Med Virol 2001; 11: 205-217.
86. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1994; 1: 136-138.
87. Osborne CS, Pasceri P, Singal R, Sukonnik T, Ginder GD, Ellis J. Amelioration of retroviral vector silencing in locus control region beta-globin-transgenic mice and transduced F9 embryonic cells. J Virol 1999; 73: 5490-5496.
88. Berkhout B, van Hemert FJ. The unusual nucleotide content of the HIV RNA genome results in a biased amino acid composition of HIV proteins. Nucleic Acids Res 1994; 22: 1705-1711.
89. Gerolami R, Uch R, Jordier F, et al. Gene transfer to hepatocellular carcinoma: transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. Cancer Gene Ther 2000; 7: 1286-1292.
90. Pfeifer A, Ikawa M, Dayn Y, Verma IM. Transgenesis by lentiviral vectors: lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc Natl Acad Sci U S A 2002; 99: 2140-2145.
91. Ginn SL, Fleming J, Rowe PB, Alexander IE. Promoter interference mediated by the U3 region in early-generation HIV-1-derived lentivirus vectors can influence detection of transgene expression in a cell-type and species-specific manner. Hum Gene Ther 2003; 14 1127-1137.
92. O'Rourke JP, Newbound GC, Kohn DB, Olsen JC, Bunnell BA. Comparison of gene transfer efficiencies and gene expression levels achieved with equine infectious anemia virus- and human immunodeficiency virus type 1-derived lentivirus vectors. J Virol 2002; 76: 1510-1515.
93. Demaison C, Parsley K, Brouns G, et al. High-level transduction and gene expression in hematopoietic repopulating cells using a human immunodeficiency [correction of immunodeficiency] virus type 1-based lentiviral vector containing an internal spleen focus forming virus promoter. Hum Gene Ther 2002; 13: 803-813.
94. Tuan D, Solomon W, Li Q, London IM. The "beta-like-globin" gene domain in human erythroid cells. Proc Natl Acad Sci U S A 1985; 82: 6384-6388.
95. Tuan DY, Solomon WB, London IM, Lee DP. An erythroid-specific, developmental-stage-independent enhancer far upstream of the human "beta-like globin" genes. Proc Natl Acad Sci U S A 1989; 86: 2554-2558.
96. Tuan D, London IM. Mapping of DNase I-hypersensitive sites in the upstream DNA of human embryonic epsilon-globin gene in K562 leukemia cells. Proc Natl Acad Sci U S A 1984; 81: 2718-2722.
97. Forrester WC, Thompson C, Elder JT, Groudine M. A developmentally stable chromatin structure in the human beta-globin gene cluster. Proc Natl Acad Sci U S A 1986; 83: 1359-1363.
98. Forrester WC, Novak U, Gelinas R, Groudine M. Molecular analysis of the human beta-globin locus activation region. Proc Natl Acad Sci U S A 1989; 86: 5439-5443.
99. Pasceri P, Pannell D, Wu X, Ellis J. Full activity from human beta-globin locus control region transgenes requires 5′HS1, distal beta-globin promoter, and 3′ beta-globin sequences. Blood 1998; 92: 653-663.
100. May C, Rivella S, Callegari J, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000; 406: 82-86.
101. May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood 2002; 99: 1902-1908.
102. Lotti F, Menguzzato E, Rossi C, et al. Transcriptional targeting of lentiviral vectors by long terminal repeat enhancer replacement. J Virol 2002; 76: 3996-4007.
103. Indraccolo S, Minuzzo S, Roccaforte F, et al. Effects of CD2 locus control region sequences on gene expression by retroviral and lentiviral vectors. Blood 2001; 98: 3607-3617.
104. Bell AC, West AG, Felsenfeld G. The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell 1999; 98: 387-396.
105. Recillas-Targa F, Pikaart MJ, Burgess-Beusse B, et al. Position-effect protection and enhancer blocking by the chicken beta-globin insulator are separable activities. Proc Natl Acad Sci U S A 2002; 99: 6883-6888.
106. Udvardy A, Maine E, Schedl P. The 87A7 chromomere. Identification of novel chromatin structures flanking the heat shock locus that may define the boundaries of higher order domains. J Mol Biol 1985; 185: 341-358.
107. Zhong XP, Krangel MS. An enhancer-blocking element between alpha and delta gene segments within the human T cell receptor alpha/delta locus. Proc Natl Acad Sci U S A 1997; 94: 5219-5224.
108. Robinett CC, O'Connor A, Dunaway M. The repeat organizer, a specialized insulator element within the intergenic spacer of the Xenopus rRNA genes. Mol Cell Biol 1997; 17: 2866-2875.
109. Modin C, Pedersen FS, Duch M. Lack of shielding of primer binding site silencer-mediated repression of an internal promoter in a retrovirus vector by the putative insulators scs, BEAD-1, and HS4. J Virol 2000; 74: 11 697-11 707.
110. Ramezani A, Hawley TS, Hawley RG. Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood 2003; 101: 4717-4724.
111. Gasser SM, Laemmli UK. Cohabitation of scaffold binding regions with upstream/enhancer elements of three developmentally regulated genes of D. melanogaster. Cell 1986; 46: 521-530.
112. Strissel PL, Espinosa R III, Rowley JD, Swift H. Scaffold attachment regions in centromere-associated DNA. Chromosoma 1996; 105: 122-133.
113. Strick R, Laemmli UK. SARs are cis DNA elements of chromosome dynamics: synthesis of a SAR repressor protein. Cell 1995; 83 1137-1148.
114. Park F, Kay MA. Modified HIV-1 based lentiviral vectors have an effect on viral transduction efficiency and gene expression in vitro and in vivo. Mol Ther 2001; 4: 164-173.
115. Park F, Ohashi K, Kay MA. The effect of age on hepatic gene transfer with self-inactivating lentiviral vectors in vivo. Mol Ther 2003; 8: 314-323.
116. Ma Y, Ramezani A, Lewis R, Hawley RG, Thomson JA. High-level sustained transgene expression in human embryonic stem cells using lentiviral vectors. Stem Cells 2003; 21: 111-117.
117. Moreau-Gaudry F, Xia P, Jiang G, et al. High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. Blood 2001; 98: 2664-2672.
118. Hanawa H, Persons DA, Nienhuis AW. High-level erythroid lineage-directed gene expression using globin gene regulatory elements after lentiviral vector-mediated gene transfer into primitive human and murine hematopoietic cells. Hum Gene Ther 2002; 13: 2007-2016.
119. Richard E, Mendez M, Mazurier F, et al. Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection. Mol Ther 2001; 4: 331-338.
120. Cui Y, Golob J, Kelleher E, Ye Z, Pardoll D, Cheng L. Targeting transgene expression to antigen-presenting cells derived from lentivirus-transduced engrafting human hematopoietic stem/progenitor cells. Blood 2002; 99: 399-408.
121. Marodon G, Mouly E, Blair EJ, Frisen C, Lemoine FM, Klatzmann D. Specific transgene expression in human and mouse CD4+ cells using lentiviral vectors with regulatory sequences from the CD4 gene. Blood 2003; 101: 3416-3423.
122. De Palma M, Venneri MA, Naldini L. In vivo targeting of tumor endothelial cells by systemic delivery of lentiviral vectors. Hum Gene Ther 2003; 14: 1193-1206.
123. Lai Z, Brady RO. Gene transfer into the central nervous system in vivo using a recombinant lentivirus vector. J Neurosci Res 2002; 67: 363-371.
124. Miyoshi H, Takahashi M, Gage FH, Verma IM. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A 1997; 94: 10 319-10 323.
125. Kostic C, Chiodini F, Salmon P, et al. Activity analysis of housekeeping promoters using self-inactivating lentiviral vector delivery into the mouse retina. Gene Ther 2003; 10: 818-821.
126. Dryja TP, Li T. Molecular genetics of retinitis pigmentosa. Hum Mol Genet 1995; 4: Spec No: 1739-1743.
127. Follenzi A, Sabatino G, Lombardo A, Boccaccio C, Naldini L. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther 2002; 13: 243-260.
128. Oertel M, Rosencrantz R, Chen YQ, et al. Repopulation of rat liver by fetal hepatoblasts and adult hepatocytes transduced ex vivo with lentiviral vectors. Hepatology 2003; 37: 994-1005.
129. Uch R, Gerolami R, Faivre J, et al. Hepatoma cell-specific ganciclovir-mediated toxicity of a lentivirally transduced HSV-TkEGFP fusion protein gene placed under the control of rat alpha-fetoprotein gene regulatory sequences. Cancer Gene Ther 2003; 10: 689-695.
130. Muschenheim F, Omarbasha B, Kardjian PM, Mondou EN. Screening for carcinoma of the prostate with prostate specific antigen. Ann Clin Lab Sci 1991; 21: 371-380.
131. Cadeddu JA, Pearson JD, Partin AW, Epstein JI, Carter HB. Relationship between changes in prostate-specific antigen and prognosis of prostate cancer. Urology 1993; 42: 383-389.
132. Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Ther 2001; 8: 628-635.
133. Zheng JY, Chen D, Chan J, Yu D, Ko E, Pang S. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A. Cancer Gene Ther 2003; 10: 764-770.
134. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002; 295: 868-872.
135. Reiser J, Lai Z, Zhang XY, Brady RO. Development of multigene and regulated lentivirus vectors. J Virol 2000; 74: 10 589-10 599.
136. Kafri T, van Praag H, Gage FH, Verma IM. Lentiviral vectors: regulated gene expression. Mol Ther 2000; 1: 516-521.
137. Ogueta SB, Yao F, Marasco WA. Design and in vitro characterization of a single regulatory module for efficient control of gene expression in both plasmid DNA and a self-inactivating lentiviral vector. Mol Med 2001; 7: 569-579.
138. Vigna E, Cavalieri S, Ailles L, et al. Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol Ther 2002; 5: 252-261.
139. Regulier E, Pereira de Almeida L, Sommer B, Aebischer P, Deglon N. Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. Hum Gene Ther 2002; 13: 1981-1990.
140. Johansen J, Rosenblad C, Andsberg K, et al. Evaluation of Tet-on system to avoid transgene down-regulation in ex vivo gene transfer to the CNS. Gene Ther 2002; 9: 1291-1301.
141. Koponen JK, Kankkonen H, Kannasto J, et al. Doxycycline-regulated lentiviral vector system with a novel reverse transactivator rtTA2S-M2 shows a tight control of gene expression in vitro and in vivo. Gene Ther 2003; 10: 459-466.
142. Salmon P, Oberholzer J, Occhiodoro T, Morel P, Lou J, Trono D. Reversible immortalization of human primary cells by lentivector-mediated transfer of specific genes. Mol Ther 2000; 2: 404-414.
143. Mitta B, Rimann M, Ehrengruber MU, et al. Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction. Nucleic Acids Res 2002; 30: e113.
144. Chang LJ, Zaiss AK. Self-inactivating lentiviral vectors and a sensitive Cre-loxP reporter system. Methods Mol Med 2003; 76 367-382.
145. Karreman S, Hauser H, Karreman C. On the use of double FLP recognition targets (FRTs) in the LTR of retroviruses for the construction of high producer cell lines. Nucleic Acids Res 1996; 24: 1616-1624.
146. Chantret I, Dupre T, Delenda C, et al. Congenital disorders of glycosylation type Ig is defined by a deficiency in dolichyl-P-mannose:Man7GlcNAc2-PP-dolichyl mannosyltransferase. J Biol Chem 2002; 277: 25 815-25 822.
147. Chantret I, Dancourt J, Dupre T, et al. A deficiency in dolichyl-P-glucose:Glc1Man9GlcNAc2-PP-dolichyl alpha3-glucosyltransferase defines a new subtype of congenital disorders of glycosylation. J Biol Chem 2003; 278: 9962-9971.
148. Richard E, Geronimi F, Lalanne M, et al. A bicistronic SIN-lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines. J Gene Med 2003; 5: 737-747.
149. Azzouz M, Martin-Rendon E, Barber RD, et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 2002; 22: 10 302-10 312.
150. Zhu Y, Feuer G, Day SL, Wrzesinski S, Planelles V. Multigene lentiviral vectors based on differential splicing and translational control. Mol Ther 2001; 4: 375-382.
151. Zhu Y, Planelles V. A multigene lentiviral vector system based on differential splicing. Methods Mol Med 2003; 76: 433-448.
152. Murthy RC, McFarland TJ, Yoken J, et al. Corneal transduction to inhibit angiogenesis and graft failure. Invest Ophthalmol Vis Sci 2003; 44: 1837-1842.
153. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000; 404: 293-296.
154. McCaffrey AP, Meuse L, Pham TT, Conklin DS, Hannon GJ, Kay MA. RNA interference in adult mice. Nature 2002; 418: 38-39.
155. Gitlin L, Karelsky S, Andino R. Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 2002; 418: 430-434.
156. Jacque JM, Triques K, Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002; 418: 435-438.
157. An DS, Wersto RP, Agricola BA, et al. Marking and gene expression by a lentivirus vector in transplanted human and nonhuman primate CD34(+) cells. J Virol 2000; 74: 1286-1295.
158. Stewart SA, Dykxhoorn DM, Palliser D, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003; 9: 493-501.
159. Rubinson DA, Dillon CP, Kwiatkowski AV, et al. A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat Genet 2003; 33: 401-406.
160. Tiscornia G, Singer O, Ikawa M, Verma IM. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci U S A 2003; 100: 1844-1848.
161. Abbas-Terki T, Blanco-Bose W, Deglon N, Pralong W, Aebischer P. Lentiviral-mediated RNA interference. Hum Gene Ther 2002; 13 2197-2201.
162. Scherr M, Battmer K, Ganser A, Eder M. Modulation of gene expression by lentiviral-mediated delivery of small interfering RNA. Cell Cycle 2003; 2: 251-257.
163. Banerjea A, Li MJ, Bauer G, et al. Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. Mol Ther 2003; 8: 62-71.
164. Li MJ, Bauer G, Michienzi A, et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther 2003; 8: 196-206.
165. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A 2003; 100 183-188.
166. Dirac AM, Bernards R. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem 2003; 278: 11 731-11 734.
167. Matta H, Hozayev B, Tomar R, Chugh P, Chaudhary PM. Use of lentiviral vectors for delivery of small interfering RNA. Cancer Biol Ther 2003; 2: 206-210.
168. Carroll R, Lin JT, Dacquel EJ, Mosca JD, Burke DS, St Louis DC. A human immunodeficiency virus type 1 (HIV-1)-based retroviral vector system utilizing stable HIV-1 packaging cell lines. J Virol 1994; 68: 6047-6051.
169. Corbeau P, Kraus G, Wong-Staal F. Efficient gene transfer by a human immunodeficiency virus type 1 (HIV-1)-derived vector utilizing a stable HIV packaging cell line. Proc Natl Acad Sci U S A 1996; 93: 14 070-14 075.
170. Yu H, Rabson AB, Kaul M, Ron Y, Dougherty JP. Inducible human immunodeficiency virus type 1 packaging cell lines. J Virol 1996; 70: 4530-4537.
171. Kaul M, Yu H, Ron Y, Dougherty JP. Regulated lentiviral packaging cell line devoid of most viral cis-acting sequences. Virology 1998; 249: 167-174.
172. Kafri T, van Praag H, Ouyang L, Gage FH, Verma IM. A packaging cell line for lentivirus vectors. J Virol 1999; 73: 576-584.
173. Klages N, Zufferey R, Trono D. A stable system for the high-titer production of multiply attenuated lentiviral vectors. Mol Ther 2000; 2: 170-176.
174. Farson D, Witt R, McGuinness R, et al. A new-generation stable inducible packaging cell line for lentiviral vectors. Hum Gene Ther 2001; 12: 981-997.
175. Xu K, Ma H, McCown TJ, Verma IM, Kafri T. Generation of a stable cell line producing high-titer self-inactivating lentiviral
176. Sparacio S, Pfeiffer T, Schaal H, Bosch V. Generation of a flexible cell line with regulatable, high-level expression of HIV Gag/Pol particles capable of packaging HIV-derived vectors. Mol Ther 2001; 3: 602-612.
177. Pacchia AL, Adelson ME, Kaul M, Ron Y, Dougherty JP. An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Virology 2001; 282: 77-86.
178. Ikeda Y, Takeuchi Y, Martin F, Cosset FL, Mitrophanous K, Collins M. Continuous high-titer HIV-1 vector production. Nat Biotechnol 2003; 21: 569-572.
179. Rolls MM, Webster P, Balba NH, Rose JK. Novel infectious particles generated by expression of the vesicular stomatitis virus glycoprotein from a self-replicating RNA. Cell 1994; 79: 497-506.
180. Kaplan AH, Swanstrom R. The HIV-1 gag precursor is processed via two pathways: implications for cytotoxicity. Biomed Biochim Acta 1991; 50: 647-653.